GSK Pledge To Lower Drug Prices In Least-developed Countries To Have Minimal Impact In Asia
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - GlaxoSmithKline's push to lower drug prices in the world's least-developed markets is not likely to have much of an impact for customers in larger and richer Asian markets but it could forestall competition from generic manufacturers
You may also be interested in...
GSK Sees Emerging Market Opportunity In Thinking Locally, Developing Locally
U.K. drug maker is increasing its sales forces in emerging markets “very significantly”, even at a time when the company is reducing its sales force in U.S. and Europe.
GSK Sees Emerging Market Opportunity In Thinking Locally, Developing Locally
SINGAPORE - GSK APJEM R&D is pretty hefty as far as acronyms go, but GlaxoSmithKline's Judith Hills wants to make sure observers do not over look the research and development title in the new GSK division
GSK Sees Emerging Market Opportunity In Thinking Locally, Developing Locally
U.K. drug maker is increasing its sales forces in emerging markets “very significantly”, even at a time when the company is reducing its sales force in U.S. and Europe.